Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-05 7:53 pm Unchanged |
2024-02-05 | 13D | Navidea Biopharmaceuticals, Inc. NAVB |
Scott John K Jr. | 110,321,886 61.800% |
0 (Unchanged) |
Filing History |
| 2023-12-21 3:32 pm Purchase |
2023-11-27 | 13D | Navidea Biopharmaceuticals, Inc. NAVB |
Scott John K Jr. | 110,321,886 61.800% |
58,190,632 (+111.62%) |
Filing History |
| 2023-07-03 6:39 pm Purchase |
2023-06-29 | 13D | Navidea Biopharmaceuticals, Inc. NAVB |
Scott John K Jr. | 52,131,254 75.040% |
21,855,950 (+72.19%) |
Filing History |
| 2023-07-03 4:01 pm Unchanged |
2023-06-21 | 13G | Navidea Biopharmaceuticals, Inc. NAVB |
Bain Irwin Allen | 4,000,000 4.730% |
0 (Unchanged) |
Filing History |
| 2023-06-30 4:01 pm Purchase |
2023-06-19 | 13G | Navidea Biopharmaceuticals, Inc. NAVB |
Bain Irwin Allen | 4,000,000 4.730% |
2,053,383 (+105.48%) |
Filing History |
| 2023-06-16 4:20 pm Purchase |
2023-06-01 | 13D | Navidea Biopharmaceuticals, Inc. NAVB |
Scott John K Jr. | 30,275,304 52.850% |
11,508,672 (+61.33%) |
Filing History |
| 2022-10-06 2:51 pm Purchase |
2022-08-24 | 13G | Navidea Biopharmaceuticals, Inc. NAVB |
Bain Irwin Allen | 1,946,617 6.230% |
1,946,617 (New Position) |
Filing History |
| 2022-09-22 3:03 pm Sale |
2022-08-24 | 13D | Navidea Biopharmaceuticals, Inc. NAVB |
Scott John K Jr. | 18,766,632 45.700% |
-533 (-0.00%) |
Filing History |
| 2022-09-14 3:25 pm Sale |
2022-08-24 | 13D | Navidea Biopharmaceuticals, Inc. NAVB |
Scott John K Jr. | 18,767,165 45.700% |
-10,139 (-0.05%) |
Filing History |
| 2022-09-09 5:59 pm Purchase |
2022-08-24 | 13D | Navidea Biopharmaceuticals, Inc. NAVB |
Scott John K Jr. | 18,777,304 45.700% |
8,491,133 (+82.55%) |
Filing History |
| 2022-04-22 2:58 pm Purchase |
2022-04-10 | 13D | Navidea Biopharmaceuticals, Inc. NAVB |
Scott John K Jr. | 10,286,171 31.600% |
54,957 (+0.54%) |
Filing History |
| 2021-07-23 4:27 pm Unchanged |
2021-07-08 | 13D | Navidea Biopharmaceuticals, Inc. NAVB |
Scott John K Jr. | 10,231,214 32.800% |
0 (Unchanged) |
Filing History |
| 2021-06-15 11:46 am Unchanged |
2021-06-01 | 13D | Navidea Biopharmaceuticals, Inc. NAVB |
Scott John K Jr. | 10,231,214 32.800% |
0 (Unchanged) |
Filing History |
| 2021-04-05 5:00 pm Purchase |
2021-04-02 | 13D | Navidea Biopharmaceuticals, Inc. NAVB |
Scott John K Jr. | 10,231,214 33.300% |
267,530 (+2.69%) |
Filing History |
| 2021-03-11 5:07 pm Unchanged |
2021-03-11 | 13D | Navidea Biopharmaceuticals, Inc. NAVB |
Scott John K Jr. | 9,963,684 33.330% |
0 (Unchanged) |
Filing History |
| 2021-03-05 5:24 pm Purchase |
2021-03-02 | 13D | Navidea Biopharmaceuticals, Inc. NAVB |
Scott John K Jr. | 9,963,684 33.330% |
1,906,383 (+23.66%) |
Filing History |
| 2020-12-29 4:15 pm Unchanged |
2020-12-23 | 13D | Navidea Biopharmaceuticals, Inc. NAVB |
Scott John K Jr. | 8,057,301 30.200% |
0 (Unchanged) |
Filing History |
| 2020-09-02 5:18 pm Purchase |
2020-08-30 | 13D | Navidea Biopharmaceuticals, Inc. NAVB |
Scott John K Jr. | 8,057,301 30.000% |
5,000 (+0.06%) |
Filing History |